Given that PI3K inhibitors were initially considered to target mainly cancer cell-intrinsic PI3K activity, we used Rag1−/− and Cd8−/− mice to verify that the observed anti-tumour effects were dependent on immune cells and, more specifically, on CD8+ T cells (Extended Data Fig. 4h). The gene discussed is CD8A; the disease is cancer.